Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124535282 | 12453528 | 2 | F | 2012 | 20160523 | 20160609 | 20160720 | EXP | US-DSJP-DSU-2015-132963 | DAIICHI | 43.46 | YR | M | Y | 190.48000 | KG | 20160718 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124535282 | 12453528 | 1 | PS | BENICAR HCT | HYDROCHLOROTHIAZIDEOLMESARTAN MEDOXOMIL | 1 | Oral | 20/12.5 MG,QD | U | 21532 | 1 | DF | FILM-COATED TABLET | QD | |||||
124535282 | 12453528 | 2 | SS | BENICAR | OLMESARTAN MEDOXOMIL | 1 | Oral | 20 MG, QD | Y | 0 | 20 | MG | TABLET | QD | |||||
124535282 | 12453528 | 3 | C | SEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 600 MG, QD | 0 | 600 | MG | TABLET | QD | ||||||
124535282 | 12453528 | 4 | C | ABILIFY | ARIPIPRAZOLE | 1 | Intramuscular | 9.75 MG,Q12 HR PRN | 0 | 9.75 | MG | ||||||||
124535282 | 12453528 | 5 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | 100 MG, QD | 0 | 100 | MG | TABLET | QD | ||||||
124535282 | 12453528 | 6 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | 200 MG, QD | 0 | 200 | MG | TABLET | QD | ||||||
124535282 | 12453528 | 7 | C | HALDOL | HALOPERIDOL | 1 | Oral | 5 MG, BID | 0 | 5 | MG | BID | |||||||
124535282 | 12453528 | 8 | C | GEODON | ZIPRASIDONE HYDROCHLORIDEIPRASIDONE MESYLATE | 1 | Oral | 80 MG, QD | 0 | 80 | MG | CAPSULE | QD | ||||||
124535282 | 12453528 | 9 | C | GEODON | ZIPRASIDONE HYDROCHLORIDEIPRASIDONE MESYLATE | 1 | Oral | 160 MG AT BEDTIME,QD | 0 | 160 | MG | CAPSULE | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124535282 | 12453528 | 1 | Hypertension |
124535282 | 12453528 | 2 | Product used for unknown indication |
124535282 | 12453528 | 3 | Schizophrenia |
124535282 | 12453528 | 4 | Product used for unknown indication |
124535282 | 12453528 | 5 | Sleep disorder |
124535282 | 12453528 | 7 | Product used for unknown indication |
124535282 | 12453528 | 8 | Bipolar disorder |
124535282 | 12453528 | 9 | Schizophrenia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
124535282 | 12453528 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124535282 | 12453528 | Constipation | |
124535282 | 12453528 | Dizziness | |
124535282 | 12453528 | Malabsorption | |
124535282 | 12453528 | Muscular weakness |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
124535282 | 12453528 | 1 | 2007 | 2014 | 0 |